US › Healthcare

Neurosense Therapeutics Ltd (NRSN)

US · Healthcare · Biotechnology

$0.52+11.33%
Last close · 2026-08-04

Key statistics

Market cap
$16.9M
Forward P/E
0.0
P/B
2.64
Book value
$-0.05
EPS (TTM)
$-0.44
52-week high
$1.98
52-week low
$0.39
50-day MA
$0.72
200-day MA
$0.87
Beta
1.60

Analyst view

Analysts rate Neurosense Therapeutics Ltd a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $6.50.

Shareholding

Insiders
32.30%
Institutions
0.96%

Largest institutional holders

FundStake
Yorkville Advisors Global, LP0.22%
Independent Advisor Alliance0.14%
UBS Group AG0.14%
Two Sigma Investments LLC0.12%
Meitav Dash Investments Ltd0.11%
Jane Street Group LLC0.08%
Commonwealth Equity Services, LLC0.06%
PNC Financial Services Group Inc0.06%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Neurosense Therapeutics Ltd — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.